Recombinant subunit dengue virus vaccine

US9198964B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Beth-Ann Griswold Coller · Woluwe-Saint-Lambert - Sint-Lambrechts-Woluwe, BE
• Vidya Pai · Rockville, US
• D. Elliot Parks · Del Mar, US
• Michele Yelmene · Del Mar, US
• Andrew J. Bett · Lansdale, US
• Timothy Martyak · Aiea, US

Key dates

• Filing date: Oct 27, 2011
• Grant date: Dec 1, 2015
• Expiry date: Oct 27, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.